Carey SA, et al. - Researchers assessed the performance of serial gene expression profiling (GEP) in dual organ transplant recipients by evaluating 18 months of follow-up findings concerning acute cellular rejection (ACR), antibody-mediated rejection (AMR), cytomegalovirus infections, biopsies, and longitudinal GEP scores among dual organ recipients (18 heart-kidney, 8 heart-liver, 1 heart-lung) matched to heart-only recipients for gender, age, and time to first GEP (AlloMap) test in a national cohort. In this largest cohort to date, no significant difference was noted between the two groups' scores, implying that dual organ transplantation alone should not be the reason to omit GEP testing from post-transplant medical management. Serial GEP testing in dual organ recipients appeared promising as it was confirmed by findings that GEP scores increased over time for heart-only and dual organ recipients and in the presence of cytomegalovirus infection.